CD8A and neoplasm: As shown in GSEA, NK1.1 blockade significantly activated the interferon pathway in CD8+ T cells, enhanced tissue residency, promoted proliferation, increased cytokine and chemokine secretion, and elevated their tumor cell‐killing capacity (Figure 5I; Figure S5K, Supporting Information).